FDA advisory committee recommends approval of tofacitinib for PsA

14:33 EDT 3 Aug 2017 | Healio

The FDA Arthritis Advisory Committee voted 10-1 today for recommending approval of the supplemental new drug application for tofacitinib in the treatment of adult patients with active psoriatic arthritis.The meeting focused on two phase 3 placebo-controlled trials that investigated the efficacy and safety of tofacitinib 5 mg twice daily and 10 mg twice daily (Xeljanz, Pfizer Inc.), as well as one ongoing phase 3 open-label, long-term extension study. Results showed tofacitinib reduced signs and symptoms of psoriatic arthritis (PsA) and improved physical function, and had a safety profile consistent with the established safety profile in rheumatoid arthritis (RA), with no new safety signals identified. Tofacitinib has previously been approved for treatment of adult patients with moderately to severely active RA and who have had an inadequate response or intolerance to methotrexate.

Original Article: FDA advisory committee recommends approval of tofacitinib for PsA


More From BioPortfolio on "FDA advisory committee recommends approval of tofacitinib for PsA"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...